Literature DB >> 35936607

Acute Hemorrhagic Necrotizing Encephalopathy in Patients with COVID-19.

Ravi Nandan1, Garima Sharma1, Khanak Nandolia1, Sudhir Saxena1, Prashant K Verma2.   

Abstract

Entities:  

Year:  2021        PMID: 35936607      PMCID: PMC9350772          DOI: 10.4103/aian.aian_528_21

Source DB:  PubMed          Journal:  Ann Indian Acad Neurol        ISSN: 0972-2327            Impact factor:   1.714


× No keyword cloud information.
To the Editor, There has been an unprecedented rise in Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While the predominant features of the disease are fever, cough, shortness of breath, and eventually respiratory failure, multiorgan system involvement is not an uncommon feature of the disease. A multitude of neurological manifestations including ischemic stroke, intracranial hemorrhages, and central nervous system (CNS) vasculitis have been reported.[1] A 10-year-old boy presented with a 5-day history of declining sensorium and fever. The patient was a diagnosed case of COVID-19 by detection of SARS-CoV-2 viral nucleic acid in a nasopharyngeal swab specimen using real-time reverse-transcription polymerase chain reaction assay (RT-PCR) 20 days back. The respiratory symptoms at the time of neurological deterioration were minimal. Chest radiograph and computed tomography of thorax revealed features of resolving pneumonia. The lumbar puncture was limited due to the traumatic tap. Coagulation profile was abnormal with a platelet count of 48. 48 thousand/mm3, prothrombin time 39.9 s (reference 13.5 s), and International Normalized Ratio 3.09 (normal range: 0.90–1.10). Laboratory analysis reveals raised serum ferritin (329 ng/mL, normal range: 7.0–140.0 ng/mL) and C-reactive protein levels (94 mg/L, normal range <6 mg/L). Interleukin-6 levels were within normal limits. D-dimer levels were also raised (1.4 μg/mL, normal range <0.50 μg/mL). Contrast-enhanced magnetic resonance imaging (MRI) of the Brain revealed hypointense signal in bilateral thalami, midbrain, pons, and left superior cerebellar peduncle on T1 and T2 weighted images with T2 hypointense rim [Figure 1]. No diffusion restriction or contrast enhancement was seen [Figure 2]. Multiple other small similar lesions were seen in bilateral cerebral and cerebellar hemispheres. There were susceptibility changes within these areas signifying hemorrhage. MR angiography revealed the irregular outline of the cavernous segment of bilateral internal cerebral and left middle cerebral arteries. MR venography was normal. On day two of admission, the patient developed hypotension with respiratory distress. Inotropes were started and the patient was kept on mechanical ventilation. Unfortunately, the patient did not survive.
Figure 1

Axial T2 (a), T1 (b) weighted MRI images of the brain show hypointense area involving bilateral thalami with a hyperintense rim on T2 weighted images. Axial FLAIR image (c) shows a hypointense area in the midbrain with a hyperintense rim. Few other similar characteristic lesions are seen in the right temporal and occipital lobe

Figure 2

Susceptibility weighted images (a, b) show hypointense signals in bilateral thalami and bilateral cerebral parenchyma suggestive of hemorrhagic areas. No restriction on the diffusion-weighted image (c) or contrast enhancement is seen on post-contrast T1 weighted image (d)

Axial T2 (a), T1 (b) weighted MRI images of the brain show hypointense area involving bilateral thalami with a hyperintense rim on T2 weighted images. Axial FLAIR image (c) shows a hypointense area in the midbrain with a hyperintense rim. Few other similar characteristic lesions are seen in the right temporal and occipital lobe Susceptibility weighted images (a, b) show hypointense signals in bilateral thalami and bilateral cerebral parenchyma suggestive of hemorrhagic areas. No restriction on the diffusion-weighted image (c) or contrast enhancement is seen on post-contrast T1 weighted image (d) Acute hemorrhagic necrotizing encephalopathy (AHNE) is a rare entity, reported in cases of viral infections, particularly influenza. The first case of COVID-19 associated AHNE was reported by Poyiadji et al.[2] in a 58-year-old female patient. Subsequently, similar cases were reported from various parts of the world with more emphasis on clinical features and pathophysiological mechanisms of neurological affliction.[34] The first case of COVID-19 related AHNE in India was reported in a 35-year-old male patient by Kumar et al.[5] Presenting features can range from headache, meningism, altered sensorium to coma, and persisting/progressive encephalopathy. There are various proposed mechanisms of neurological involvement in COVID-19. There is evidence of direct entry of the virus through the ACE-2 receptor, either through the blood-brain barrier or neuronal transport.[67] Indirect mechanisms like hypercoagulable state from systemic inflammation, intra-cranial cytokine storm, post-infection immune-mediated responses, endothelial damage due to direct viral invasion resulting in microangiopathy are also hypothesized.[89] Of most notable interest is the hypothesis of intracranial cytokine storm which results in the breakdown of the blood-brain barrier without any evidence of direct viral invasion or postinfective demyelination. The opening CSF pressure and protein may be elevated. Most of the cases reported negative SARS-CoV-2 PCR of the CSF samples. The most characteristic imaging findings include symmetric, multifocal T2/FLAIR hyperintense in cerebral white matter, brain stem, and cerebellum with areas of hemorrhage within. In most of the cases, there is bilateral thalamic involvement,[10] as in typical cases of AHNE. Contrast-enhanced images may show a ring of enhancement. Although outcome data are limited, early detection and prompt treatment may useful. High-dose corticosteroids, immune-modulators, and plasmapheresis are available treatment options and can lead to recovery in the early stages. To conclude, AHNE should be considered in COVID-19 patients with severe encephalopathy. Awareness about this entity will lead to a better understanding of the pathophysiological mechanism, associations, and risk factors resulting in better patient care.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  10 in total

1.  Acute necrotizing encephalopathy of childhood: correlation of MR findings and clinical outcome.

Authors:  A M Wong; E M Simon; R A Zimmerman; H-S Wang; C-H Toh; S-H Ng
Journal:  AJNR Am J Neuroradiol       Date:  2006-10       Impact factor: 3.825

Review 2.  Neurological manifestations of COVID-19: A brief review.

Authors:  Kirti Sachdev; Sumita Agrawal; Pranav Ish; Nitesh Gupta; Kapil Raheja
Journal:  Indian J Med Res       Date:  2020 Jul & Aug       Impact factor: 2.375

Review 3.  Neuromechanisms of SARS-CoV-2: A Review.

Authors:  Marcos F DosSantos; Sylvie Devalle; Veronica Aran; Daniela Capra; Natália Roberta Roque; Juliana de Mattos Coelho-Aguiar; Tânia Cristina Leite de Sampaio E Spohr; Janice Gonçalves Subilhaga; Cláudia Maria Pereira; Isabella D'Andrea Meira; Paulo Niemeyer Soares Filho; Vivaldo Moura-Neto
Journal:  Front Neuroanat       Date:  2020-06-16       Impact factor: 3.856

4.  COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia.

Authors:  Luke Dixon; James Varley; Anastassia Gontsarova; Dermot Mallon; Francesca Tona; David Muir; Asad Luqmani; Ieuan Harri Jenkins; Richard Nicholas; Brynmor Jones; Alex Everitt
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-05-26

5.  Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms.

Authors:  Abdul Mannan Baig; Areeba Khaleeq; Usman Ali; Hira Syeda
Journal:  ACS Chem Neurosci       Date:  2020-03-13       Impact factor: 4.418

6.  Acute Necrotizing Encephalitis as a Probable Association of COVID-19.

Authors:  Neeraj Kumar; Subhash Kumar; Abhyuday Kumar; Binod K Pati; Amarjeet Kumar; Chandramani Singh; Asim Sarfraz
Journal:  Indian J Crit Care Med       Date:  2020-10

7.  Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid.

Authors:  Johan Virhammar; Eva Kumlien; David Fällmar; Robert Frithiof; Sven Jackmann; Mattias K Sköld; Mohamed Kadir; Jens Frick; Jonas Lindeberg; Henrik Olivero-Reinius; Mats Ryttlefors; Janet L Cunningham; Johan Wikström; Anna Grabowska; Kåre Bondeson; Jonas Bergquist; Henrik Zetterberg; Elham Rostami
Journal:  Neurology       Date:  2020-06-25       Impact factor: 9.910

8.  COVID-19: consider cytokine storm syndromes and immunosuppression.

Authors:  Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson
Journal:  Lancet       Date:  2020-03-16       Impact factor: 79.321

9.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

10.  COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features.

Authors:  Neo Poyiadji; Gassan Shahin; Daniel Noujaim; Michael Stone; Suresh Patel; Brent Griffith
Journal:  Radiology       Date:  2020-03-31       Impact factor: 11.105

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.